Vaccines Targeting Gliomas: Antigens Matter.

Abstract

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. December 15, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.02616 Journal of Clinical Oncology - published online before print January 9, 2023 PMID: 36623232 Vaccines Targeting Gliomas: Antigens Matter Michael Platten , MD1,2,3,4xMichael PlattenSearch for articles by this author and Niklas Grassl, MD1,2,4xNiklas GrasslSearch for articles by this author Show More 1DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany2Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany3Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany4DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany https://doi.org/10.1200/JCO.22.02616 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Michael PlattenCollection and assembly of data: Niklas GrasslManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTVaccines Targeting Gliomas: Antigens MatterThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael PlattenStock and Other Ownership Interests: EvotechConsulting or Advisory Role: Novartis (Inst), Monte Rosa Therapeutics (Inst)Research Funding: Bayer (Inst), Merck (Inst), Pfizer (Inst), Novartis (Inst), Roche/Genentech (Inst)Patents, Royalties, Other Intellectual Property: Diagnosing and treating IDH1-mutant cancers, treating H3.3K27M-mutant cancers, treating cancers with AHR antagonistsNo other potential conflicts of interest were reported. Companion Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma